Patrys CEO and MD, Dr James Campbell, was interviewed by Proactive’s Andrew Scott to discuss the importance of today’s announcement that batch specification testing for GMP PAT-DX1 material has been successfully completed.
He also provided an overview of upcoming activities, as Patrys prepares to initiate a phase 1 clinical study of PAT-DX1 in the second half of 2023.
Check out the interview here: